Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients

This study has been completed.
Information provided by:
Gruppo Italiano per lo Studio del Mieloma Multiplo Identifier:
First received: October 4, 2005
Last updated: NA
Last verified: October 2005
History: No changes posted

The purpose of this study is to determine whether the association of Thalidomide to Melphalan and Prednisone is effective in the treatment of newly diagnosed elderly multiple myeloma.

Condition Intervention Phase
Multiple Myeloma
Drug: Thalidomide
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase III, Prospective, Open Label, Multicenter, Randomized Trial of Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone as First Line Therapy in Myeloma Patients Aged >65.

Resource links provided by NLM:

Further study details as provided by Gruppo Italiano per lo Studio del Mieloma Multiplo:

Primary Outcome Measures:
  • Response Rate
  • Progression Free Survival
  • Event Free Survival

Secondary Outcome Measures:
  • Safety
  • Overall Survival

Estimated Enrollment: 400
Study Start Date: January 2002
Estimated Study Completion Date: May 2010
Detailed Description:

Intermittent courses of Melphalan and Prednisone (MP) have been the first line therapy in multiple myeloma, for many years.

Advances in systemic and supportive therapy increased remission rates and overall survival, but multiple myeloma still remains an incurable haematological malignancy. Several preliminary studies demonstrate the efficacy of thalidomide in refractory and relapsed multiple myeloma with an overall response rate of 30 to 60%.

Due to its activity, Thalidomide will be evaluated in association with MP in a randomized study for newly diagnosed myeloma patients not eligible for high-dose chemotherapy.


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • untreated myeloma patients
  • age >65 years of age or younger but excluded from transplant procedure
  • Durie & Salmon stage II or III myeloma and measurable disease.
  • Patients agreed to use contraception

Exclusion Criteria:

  • other cancer
  • psychiatric disease and any grade 2 peripheral neuropathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00232934

Divisionedi Ematologia - Ospedali Riuniti
Bergamo, Italy, 24127
Istituto di Ematologia e Oncologia Medica "Seragnoli"- Università di Bologna
Bologna, Italy, 40138
Divisione di Ematologia - Az. Osp. S.Croce Carle
Cuneo, Italy, 26100
U.O. di Ematologia e Trapianto di Cellule Staminali, IRCCS Casa Sollievo della Sofferenza
Foggia, Italy, 71013
Ematologia - H.S. Gerardo
Monza, Italy, 20052
Cattedra e Divisione di Ematologia Università Federico II
Napoli, Italy, 80131
Divisione di Ematologia e Trapianto di Midollo Osseo- Ospedale Cervello
Palermo, Italy, 90146
Clinica Medica I, Policlinico Monteluce
Perugia, Italy, 06123
Divisione di Ematologia Ospedali Riuniti
Reggio Calabria, Italy, 89100
Cattedra e Divisione di Ematologia Università TOR Vergata Ospedale S.Eugenio
Roma, Italy, 00100
Dipartimento di Biotecnologie ed Ematologia - Università La Sapienza
Roma, Italy, 00161
Istituto di Ematologia - Università Cattolica
Roma, Italy, 00168
Divisione di Ematologia dell'Università di Torino, Azienda Ospedaliera S.Giovanni Battista
Torino, Italy, 10126
Sponsors and Collaborators
Gruppo Italiano per lo Studio del Mieloma Multiplo
Principal Investigator: Mario Boccadoro, MD Divisione di Ematologia dell'Università di Torino, Azienda Ospedaliera S.Giovanni Battista, Torino, Italy
Study Director: Antonio Palumbo, MD Divisione di Ematologia dell'Università degli Studi di Torino, Azienda Ospedaliera S.Giovanni Battista, Torino, Italy
  More Information

Additional publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00232934     History of Changes
Other Study ID Numbers: GISMM2001-A
Study First Received: October 4, 2005
Last Updated: October 4, 2005
Health Authority: Italy: Ministry of Health

Keywords provided by Gruppo Italiano per lo Studio del Mieloma Multiplo:
Elderly patients

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Vascular Diseases
Alkylating Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Anti-Inflammatory Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Hormonal
Growth Inhibitors
Growth Substances
Hormones processed this record on November 24, 2014